Form 8-K - Current report:
SEC Accession No. 0001104659-23-066171
Filing Date
2023-05-30
Accepted
2023-05-30 17:20:09
Documents
15
Period of Report
2023-05-30
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2317351d1_8k.htm   iXBRL 8-K 33175
2 EXHIBIT 16.1 tm2317351d1_ex16-1.htm EX-16.1 3961
6 GRAPHIC tm2317351d1_ex16-1img001.jpg GRAPHIC 23073
7 GRAPHIC tm2317351d1_ex16-1img002.jpg GRAPHIC 35445
  Complete submission text file 0001104659-23-066171.txt   296880

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20230530.xsd EX-101.SCH 3039
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20230530_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20230530_pre.xml EX-101.PRE 22599
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2317351d1_8k_htm.xml XML 3707
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 23977835
SIC: 2834 Pharmaceutical Preparations